戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ate cancer versus normal prostate and benign prostatic hypertrophy.
2 carcinomas versus normal prostate and benign prostatic hypertrophy.
3   One required prostate resection for benign prostatic hypertrophy.
4 per 1000 discharges for uncomplicated benign prostatic hypertrophy.
5  smooth muscle cells in patients with benign prostatic hypertrophy.
6 latter resembling uterine leiomyomatosis and prostatic hypertrophy.
7                 The patient developed benign prostatic hypertrophy and chronic obstructive pulmonary
8 orbidity and mortality in the form of benign prostatic hypertrophy and prostate adenocarcinoma.
9 o improved non-invasive therapies for benign prostatic hypertrophy and prostate cancer.
10  human diseases, including hirsutism, benign prostatic hypertrophy, and prostate cancer, but all avai
11 cess critical for normal development, benign prostatic hypertrophy, and tumorigenesis.
12 es of prostate cancer and 20 cases of benign prostatic hypertrophy (BPH) by immunohistochemistry and
13 tment of Hypertension and symptomatic benign prostatic hypertrophy (BPH).
14  a definite role in the management of benign prostatic hypertrophy, but stents must be used with caut
15 atively low (18)F-DCFBC PET uptake in benign prostatic hypertrophy lesions, compared with cancer in t
16 evels of receptor in normal glands or benign prostatic hypertrophy specimens.
17 ificantly lower (18)F-DCFBC uptake in benign prostatic hypertrophy than primary tumors (median maximu
18 l transcript was found in control and benign prostatic hypertrophy tissues.
19  a cornerstone of prostate cancer and benign prostatic hypertrophy treatment.
20 m 4.4% (osteoporosis trials) to 100% (benign prostatic hypertrophy trials).
21 wing no histological manifestation of benign prostatic hypertrophy) using in situ hybridization with